LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that results from a Phase 1 study of STA-9090, a potent, second-generation Hsp90 inhibitor, will be the subject of a poster discussion session in the Developmental Therapeutics session at the American Society for Clinical Oncology (ASCO) Annual Meeting 2010 on Saturday, June 5 at 12:30 p.m.
